About the firm
A partner-led firm for cross-border life sciences.
We advise biotech and pharmaceutical companies on licensing, partnerships and NewCo formation between Asia, Europe and North America. Partner-owned and selective by design, with teams in Hong Kong, Shanghai, Zurich and Chicago.
- Model
- Partner-led
- Senior attention from the first call
- Reach
- Three continents
- Hong Kong · Shanghai · Zurich · Chicago
- Track record
- US$2B+
- Transaction value across 15+ cross-border deals
- Ownership
- Partner-owned
- No outside financial sponsors
Our view
The best science is being developed across borders. So are the partnerships that matter.
Three principles, without exception.
Not unusual on paper. Unusual in practice.
Principle 01
Partner-led, end to end
The partner who signs a mandate runs it through to close. No mid-deal handoffs and no associate-only readouts.
In practice
One accountable partner · Weekly partner touchpoint · Continuity through close
Principle 02
Selective, by design
We work on a small number of mandates at a time and decline more than we accept. Conflicts are checked in writing, not by word of mouth.
In practice
Written conflict screening · Information barriers · Fewer, deeper engagements
Principle 03
Discretion as the service
We do not market deals or name counterparties without consent. Our work shows in our clients’ results.
In practice
NDA-first conversations · No league tables · No house deal flow
Footprint
One firm. Four teams.
Senior coverage in every region and the same partners on every mandate. Not a network of offices, but one team that works across time zones.
| Team | Region | Local time |
|---|---|---|
| Hong Kong | Headquarters · Asia-Pacific | |
| Shanghai | Greater China | |
| Zurich | Europe | |
| Chicago | Americas |
A short history
Built for cross-border life-science work.
2018 · Origin
Hong Kong
The practice opens in Hong Kong, founded by partners with global pharma business development and Greater China biotech backgrounds.
2019–2021 · Reach
Shanghai and Zurich
Coverage of mainland China and Europe deepens, and the first multi-jurisdiction NewCo formation closes.
2022–2023 · Coverage
Modalities and the Americas
Cell and gene therapy, antibody-drug conjugate and bispecific coverage is formalised, and coverage of the Americas is added.
2024–today · Scale
Publications
Dragon Pipeline and BioDeal Weekly launch, alongside a growing portfolio of executed cross-border mandates.
The first conversation is quiet.
Tell us what you are working on. We reply within one business day, and we can sign an NDA before you share any materials.